Investor Overview

Corporate Profile
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$1.66
Change (%) Stock is Up 0.01 (0.61%)
Volume39,758
Data as of 05/26/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
05/16/17Histogenics Corporation to Present at Upcoming Industry Conferences
WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Management will be presenting at several upcoming industry conferences.  12th World Advanced Therapies & Regenerative Medicine Congress – London, England (May 17-19, 2017) Adam Gridley, Histogenics’ CEO, will be participating in several panels disc... 
Printer Friendly Version
05/15/17Histogenics Corporation Receives Innovation Award
‒ Histogenics Recognized by the Smaller Business Association of New England (SBANE) as One of the Most Innovative Companies in the Region ‒ ‒ NeoCart® and Tissue Generation Platform Seen as a Potential Leading Solution to Treat Cartilage Defects ‒ WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that it was one of the ... 
Printer Friendly Version
05/11/17Histogenics Corporation Announces First Quarter 2017 Financial and Operating Results
‒ NeoCart® Phase 3 Clinical Trial Enrollment Near Completion ‒ ‒ NeoCart Approval Pathway in Japan Defined After Successful Conclusion of Discussions with the Japan Pharmaceuticals and Medical Devices Agency ‒ ‒ Publication of Additional Data to Support Potential Approval and Commercialization of NeoCart ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒ WALTHAM, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerativ... 
Printer Friendly Version
05/08/17Histogenics Announces Agreement With the Japan Pharmaceuticals and Medical Devices Agency Regarding Japanese Regulatory Pathway for NeoCart®
– Long history and significant US data package may enable full Marketing and Manufacturing Authorization of NeoCart subject to successful completion of small confirmatory clinical trial in Japan – – PMDA Consultations concluded in first quarter of 2017 encompass all parts of potential regulatory submission including:  Clinical Trial, Quality/Manufacturing and Non-Clinical Safety – – Japanese cartilage repair market estimated to be second largest in the world with established reimbursement, a... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
06/01/17
Histogenics Corp at the Forum for Innovative Regenerative Medicine (FIRM) – Regenerative Medicine Crossroad® #4 Conference
LocationTokyoJP
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Featured Documents
View the Company Profile
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.